title: [Clinical Analysis of 4 AML Patients Aged Over 80 Years Treated with Chemotherapy Combined with Haploidentical Hematopoietic Stem Cell Infusion].
abstract: OBJECTIVE
  To investigate the efficacy and safety of MA (mitoxantrone and cytarabine) regimen chemotherapy combined with granulocyte-colony stimulating factor (G-CSF)-mobilized family related HLA-haploidentical donor peripheral blood hematopoietic stem cell (G-PBHSC) infusion for the treatment of acute myeloid leukemia (AML) patients aged over 80 years.
  
  
  METHODS
  Four elderly patients with AML were treated in Chinese Second Artillery General Hospital from August 2008 to September 2013. The proportion of male to female was 1 : 3 and the median age 83 (80-85) years. All patients received programmed infusions of G-PBHSC after MA regimen chemotherapy without graft-versus-host disease (GVHD) prophylaxis. After complete remission (CR), patients only received G-PBHSC infusion without chemotherapy.
  
  
  RESULTS
  Three cases achieved CR and their disease free survival (DFS) time was 18, 8, 6 months, respectively. 1 case did not reach remission after 2 cycles chemotherapy. The median overall survival (OS) time was 10 (3-20) months. No GVHD was observed in any of the patients during treatment. Concludsion: The combination of chemotherapy and programmed haploidentical G-PBHSC infusion is an alternative approach for AML patients aged over 80 years.
authors.affiliation: Department of Hematology, The Second Artillery General Hospital of Chinese PLA, Beijing 100088, China.
authors.forename: Juan
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Hematology, The Second Artillery General Hospital of Chinese PLA, Beijing 100088, China. E-mail: sunwanjun1974@sohu.com.
authors.forename: Wan-Jun
authors.initials: WJ
authors.lastname: Sun
authors.affiliation: Department of Hematology, The Second Artillery General Hospital of Chinese PLA, Beijing 100088, China.
authors.forename: Hong-Xia
authors.initials: HX
authors.lastname: Zhao
authors.affiliation: Department of Hematology, The Second Artillery General Hospital of Chinese PLA, Beijing 100088, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Hematology, The Second Artillery General Hospital of Chinese PLA, Beijing 100088, China.
authors.forename: Ya-Jing
authors.initials: YJ
authors.lastname: Huang
authors.affiliation: Department of Hematology, The Second Artillery General Hospital of Chinese PLA, Beijing 100088, China.
authors.forename: Xiao-Qin
authors.initials: XQ
authors.lastname: Xi
authors.affiliation: Department of Hematology, The Second Artillery General Hospital of Chinese PLA, Beijing 100088, China.
authors.forename: Hai-Lan
authors.initials: HL
authors.lastname: Hu
mesh_terms: D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D003561:Cytarabine; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease; D016179:Granulocyte Colony-Stimulating Factor; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells; D006801:Humans; D015470:Leukemia, Myeloid, Acute; D008297:Male; D008942:Mitoxantrone; D012074:Remission Induction
chemical_list: D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D008942:Mitoxantrone